Diaceutics PLC (LON:DXRX – Get Free Report) insider Nick Roberts purchased 112 shares of Diaceutics stock in a transaction that occurred on Monday, September 30th. The stock was bought at an average cost of GBX 134 ($1.79) per share, for a total transaction of £150.08 ($200.75).
Nick Roberts also recently made the following trade(s):
- On Wednesday, August 28th, Nick Roberts bought 113 shares of Diaceutics stock. The shares were acquired at an average cost of GBX 134 ($1.79) per share, for a total transaction of £151.42 ($202.54).
Diaceutics Trading Down 1.1 %
LON DXRX opened at GBX 132 ($1.77) on Friday. The company has a debt-to-equity ratio of 2.93, a quick ratio of 9.92 and a current ratio of 4.85. The company has a market capitalization of £111.50 million, a price-to-earnings ratio of -4,400.00 and a beta of 0.58. The company’s 50-day simple moving average is GBX 128.97 and its two-hundred day simple moving average is GBX 120.61. Diaceutics PLC has a one year low of GBX 82 ($1.10) and a one year high of GBX 136 ($1.82).
Analysts Set New Price Targets
Get Our Latest Stock Report on Diaceutics
About Diaceutics
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.
Further Reading
- Five stocks we like better than Diaceutics
- The 3 Best Blue-Chip Stocks to Buy Now
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Conference Calls and Individual Investors
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Why Are These Companies Considered Blue Chips?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.